SVB Leerink initiated coverage of Imara (NASDAQ:IMRA) with an “outperform” rating and $25 price target in 12 months. The stock closed at $15.75 on April 3. Imara is focused on developing and commercializing novel...
SVB Leerink initiated coverage of Mereo BioPharma Group PLC (NASDAQ:MREO) with an “outperform” rating and price target of $8. The stock closed at $2.89 on Oct. 9. “We believe this rare disease-focused biopharma company...
SVB Leerink raised its price target for InflaRx N.V. (NASDAQ:IFRX) to $67 from $42, citing a potentially larger orphan market for the company’s lead indication. The stock closed at $43.77 on April 9. “We have been...
Leerink is recommending that healthcare investors, after a market-beating 2017, look for ways to keep up with what will likely be a strong broader stock market in 2018. “We encourage use of higher-beta healthcare and...